Target intelligence / Profile preview

Pyrazinamidase/nicotinamidase (PncA) (PncA)

Target
PncA
Molecular classification
Enzyme, Hydrolase, Amidase, Nicotinamidase, Metal-binding protein
01

Overview

Pyrazinamidase/nicotinamidase (PncA) is a critical bacterial enzyme, primarily characterized in Mycobacterium tuberculosis, that functions as a nicotinamidase within the NAD+ salvage pathway by converting nicotinamide to nicotinic acid (UniProt P9WNY5). Beyond its metabolic role, PncA is the essential activator of the first-line antitubercular prodrug pyrazinamide (PZA), catalyzing its conversion into the active form, pyrazinoic acid (POA) (Scorpio & Zhang, 1996). The active POA moiety disrupts the bacterial membrane potential and inhibits multiple targets, including RpsA and PanD, which is particularly effective against non-replicating persisters in acidic environments (Zhang et al., 2014). Mutations across the pncA gene are the most common cause of clinical resistance to pyrazinamide, making it a vital biomarker for molecular drug susceptibility testing (Jureen et al., 2008). Notably, Mycobacterium bovis exhibits innate resistance to PZA due to a characteristic H57D mutation in the pncA gene (Scorpio et al., 1997). The enzyme's activity is dependent on metal ions, typically iron or manganese, which are coordinated at the active site to facilitate the hydrolytic reaction (FEBS J, 2008).

Other names
PyrazinamidaseNicotinamidasePZaseNicotinamide amidohydrolasepncA
02

Mechanism of action

Enzymatic activation of the prodrug pyrazinamide into its active bactericidal form, pyrazinoic acid, which subsequently disrupts bacterial membrane potential and cellular energetics.

03

Biological functions

NAD+ salvage pathwayNicotinamide metabolismProdrug activation
04

Disease associations

InfectionTuberculosis
05

Safety considerations

High diversity of resistance-conferring mutations in the pncA geneInnate resistance in Mycobacterium bovis due to H57D mutationReliability issues in phenotypic drug susceptibility testing due to pH-dependent activity
06

Interacting drugs

Pyrazinamide
07

Biomarkers

pncA gene mutationsPyrazinamidase activity levels

Beyond the preview

Go deeper on Pyrazinamidase/nicotinamidase (PncA) (PncA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyrazinamidase/nicotinamidase (PncA) (PncA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call